Transdermal Estradiol Treatment for Postpartum Depression: A Pilot, Randomized Trial

Journal of Clinical Psychopharmacology

Volumn 35, Issue 4, 2015, Pages 389-395

  Wisner, Katherine L ^a   Sit, Dorothy K Y ^b   Moses Kolko, Eydie L ^b   Driscoll, Kara E ^a   Prairie, Beth A ^c   Stika, Catherine S ^a   Eng, Heather F ^d   Dills, John L ^d   Luther, James F ^d   Wisniewski, Stephen R ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cytochrome P450 3A4; estradiol dose requirement; postpartum depression; postpartum mania; randomized clinical trial; transdermal estradiol

Indexed keywords

CYTOCHROME P450 3A4; ESTRADIOL; ESTRONE; MEDROXYPROGESTERONE; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; ESTRADIOL BLOOD LEVEL; FEMALE; GLUCURONIDATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOMANIA; OBESITY; PREGNANCY; PRIORITY JOURNAL; PSYCHOSIS; PUERPERAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL; SULFATION; TRANSDERMAL PATCH; VISUAL HALLUCINATION; WEIGHT CONTROL; CUTANEOUS DRUG ADMINISTRATION; DEPRESSION, POSTPARTUM; PILOT STUDY; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADULT; DEPRESSION, POSTPARTUM; ESTRADIOL; FEMALE; HUMANS; PILOT PROJECTS; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936935483     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000351     Document Type: Article

References (55)

1. Angold A, Worthman C. Puberty onset of gender differences in rates of depression: a developmental, epidemiological, and neuroendocrine perspective. J Affect Disord. 1993;29:145-158.
2. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med. 1998;28:9-19.
3. Lokuge S, Frey BN, Foster JA, et al. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry. 2011;72:e1563-e1569.
4. Rapkin AJ, Mikacich JA, Moatakef-Imani B, et al. The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders. Curr Psychiatry Rep. 2002;4:419-428.
5. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15:797-817.
6. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;119:1-8.
7. Pearson RM, Evans J, Kounali D, et al. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry. 2013;70: 1312-1319.
8. Beck CT. The effects of postpartum depression on child development: a meta-analysis. Arch Psychiatr Nurs. 1998;12:12-20.
9. Gundlah C, Kohama SG, Mirkes SJ, et al. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res Mol Brain Res. 2000;76:191-204.
10. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000; 157:924-930.
11. Moses-Kolko EL, Berga SL, Kalro B, et al. Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol. 2009;52:516-529.
12. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279-307.
13. Bethea CL, Mirkes SJ, Shively CA, et al. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry. 2000; 47:562-576.
14. Pecins-Thompson M, Bethea CL. Ovarian steroid regulation of serotonin-1A autoreceptor messenger RNA expression in the dorsal raphe of rhesus macaques. Neuroscience. 1999;89:267-277.
15. Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17B-estradiol treatment on the serotonin 5-HT1A receptor mRNA and binding levels in the rat brain. Synapse. 2000;35:39-44.
16. McEwen BS, Akama KT, Spencer-Segal JL, et al. Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci. 2012;126:4-16.
17. Woolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci. 1992; 12:2549-2554.
18. Rivera HM, Bethea CL. Ovarian steroids increase PSD-95 expression and dendritic spines in the dorsal raphe of ovariectomized macaques. Synapse. 2013;67:897-908.
19. Bethea CL, Reddy AP, Tokuyama Y, et al. Protective actions of ovarian hormones in the serotonin system of macaques. Front Neuroendocrinol. 2009;30:212-238.
20. Amantea D, Russo R, Bagetta G, et al. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res. 2005;52:119-132.
21. WuWF, TanXJ, DaiYB, et al. Targeting estrogen receptor beta in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2013;110:3543-3548.
22. Ryan J, Ancelin ML. Polymorphisms of estrogen receptors and risk of depression: therapeutic implications. Drugs. 2012;72:1725-1738.
23. Calmarza-Font I, Lagunas N, Garcia-Segura LM. Antidepressive and anxiolytic activity of selective estrogen receptor modulators in ovariectomized mice submitted to chronic unpredictable stress. Behav Brain Res. 2012;227:287-290.
24. Furuta M, Numakawa T, Chiba S, et al. Estrogen, predominantly via estrogen receptor alpha, attenuates postpartum-induced anxiety-and depression-like behaviors in female rats. Endocrinology. 2013;154: 3807-3816.
25. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006; 13:411-422.
26. Jacobs E, D'Esposito M. Estrogen shapes dopamine-dependent cognitive processes: implications for women's health. J Neurosci. 2011;31: 5286-5293.
27. Dreher JC, Schmidt PJ, Kohn P, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A. 2007; 104:2465-2470.
28. Smith CT, Sierra Y, Oppler SH, et al. Ovarian cycle effects on immediate reward selection bias in humans: a role for estradiol. J Neurosci. 2014;34: 5468-5476.
29. Protopopescu X, Pan H, Altemus M, et al. Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. Proc Natl Acad Sci U S A. 2005;102:16060-16065.
30. van Wingen GA, Ossewaarde L, Backstrom T, et al. Gonadal hormone regulation of the emotion circuitry in humans. Neuroscience. 2011;191: 38-45.
31. Shafir T, Love T, Berent-Spillson A, et al. Postmenopausal hormone use impact on emotion processing circuitry. Behav Brain Res. 2012;226: 147-153.
32. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-933.
33. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786.
34. Ahokas A, Kaukoranta J, Wahlbeck K, et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiological 17B-estradiol: a preliminary study. J Clin Psychiatry. 2001;62:332-336.
35. Perheentupa A, Ruokonen A, Tapanainen JS. Transdermal estradiol treatment suppresses serum gonadotropins during lactation without transfer into breast milk. Fertil Steril. 2004;82:903-907.
36. Prairie BA, Wisniewski SR, Luther JF, et al. Postpartum lipid levels in women with major depression. J Womens Health (Larchmt). 2012;21: 534-538.
37. Booker DE, Pahyl IR. Control of postpartum breast engorgement with oral contraceptives. Am J Obstet Gynecol. 1967;98:1099-1101.
38. Williams JBW, Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale With Atypical Depression Supplement (SIGH-ADS). New York, NY: New York State Psychiatric Institute; 2003.
39. Asberg M, Cronholm B, Sjoqvist F, et al. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J. 1970;4: 18-21.
40. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline.J ClinPsychopharmacol. 2006;26:353-360.
41. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220-229.
42. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77:S13-S18.
43. Westhoff CL, Reinecke I, Bangerter K, et al. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Contraception. 2014;90:272-279.
44. Westhoff CL, Torgal AT,Mayeda ER, et al. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception. 2012;85:465-469.
45. Wade AG, Haring J. A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. Int Clin Psychopharmacol. 2010;25:288-296.
46. Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998; 105:1082-1090.
47. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103-141.
48. Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013; 41:263-269.
49. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84:248-253.
50. Chen H, Yang K, Choi S, et al. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37:1841-1847.
51. Jeong H, Choi S, Song JW, et al. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38:62-75.
52. Wen X, Donepudi AC, Thomas PE, et al. Regulation of hepatic phase II metabolism in pregnant mice. J Pharmacol Exp Ther. 2013;344:244-252.
53. Kodama S, Negishi M. Sulfotransferase genes: regulation by nuclear receptors in response to xeno/endo-biotics. Drug Metab Rev. 2013;45: 441-449.
54. Itaaho K, Mackenzie PI, Ikushiro S, et al. The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2008;36:2307-2315.
55. Ohkita C, Goto M. Increased 6-hydroxycortisol excretion in pregnant women: implication of drug-metabolizing enzyme induction. DICP. 1990; 24:814-816.